L&G Pharma Breakthrough UCITS USD
| Issuer: L&G ETFs |
| Asset Class: Equity |
| TER: 49bps |
| Trading Currency: GBX |
| Pays Income: False |
| Listing Date: 23 Jan 2018 |
| Ticker: BIGT |
| ISIN: IE00BF0H7608 |
This fund provides targeted exposure to the global pharmaceutical and biotechnology sectors, focusing on companies poised for significant breakthroughs. It invests in firms at the forefront of medical innovation, spanning areas like drug discovery, clinical trials, advanced therapies such as gene editing, and medical device technology. The portfolio is constructed to capture the growth potential of businesses developing novel treatments for a wide range of diseases. By tracking a specialized index, the fund offers a diversified approach to a high-growth, research-intensive industry, moving beyond traditional large-cap pharmaceutical giants to include smaller, more agile innovators.
This investment is suitable for investors with a higher risk tolerance and a long-term perspective, who believe in the continuous advancement of medical science and healthcare technology. It can serve as a satellite holding within a broader, diversified portfolio, adding a thematic tilt towards a sector driven by powerful secular tailwinds such as ageing populations, increasing healthcare spending globally, and rapid technological progress. Investors should be aware that the biotechnology and pharmaceutical industries can be subject to high volatility due to factors like clinical trial outcomes, regulatory approvals, and patent expirations.
The rationale for investing is to gain access to the potential upside from disruptive innovations in medicine. The fund captures a basket of companies that are working on next-generation treatments, which could lead to substantial growth if their research and development efforts prove successful. Instead of trying to pick individual winners in a complex and specialist field, this product offers a diversified way to invest in the broader theme of pharmaceutical breakthroughs. This approach mitigates single-company risk while maintaining exposure to the sector's overall innovation and growth trajectory.
